Cloud-clone
SKU:CEE038Hu
ELISA Kit for Neurofilament, Light Polypeptide (NEFL)
ELISA Kit for Neurofilament, Light Polypeptide (NEFL)
Couldn't load pickup availability
Enzyme-linked immunosorbent assay for Antigen Detection.
Product No.
CEE038Hu
Organism Species
Homo sapiens (Human).
Sample Type
serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
Test Method
Competitive Inhibition
Assay Length
2h
Detection Range
123.5-10,000pg/mL
Sensitivity
The minimum detectable dose of this kit is typically less than 49.3pg/mL.
UOM
48T 96T 96T*5 96T*10 96T*100
Specificity
This assay has high sensitivity and excellent specificity for detection of Neurofilament, Light Polypeptide (NEFL).
No significant cross-reactivity or interference between Neurofilament, Light Polypeptide (NEFL) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Neurofilament, Light Polypeptide (NEFL) and the recovery rates were calculated by comparing the measured value to the expected amount of Neurofilament, Light Polypeptide (NEFL) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 84-98 | 93 |
| EDTA plasma(n=5) | 81-104 | 88 |
| heparin plasma(n=5) | 98-105 | 101 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Neurofilament, Light Polypeptide (NEFL) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Neurofilament, Light Polypeptide (NEFL) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Neurofilament, Light Polypeptide (NEFL) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 85-101% | 80-94% | 95-103% | 88-95% |
| EDTA plasma(n=5) | 91-105% | 80-104% | 95-105% | 80-99% |
| heparin plasma(n=5) | 79-94% | 79-101% | 85-104% | 94-102% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
| Standard | 2 | Standard Diluent | 1×20mL |
| Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
| Detection Reagent B | 1×120µL | Assay Diluent B | 1×12mL |
| TMB Substrate | 1×9mL | Stop Solution | 1×6mL |
| Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 50µL standard or sample to each well.
And then add 50µL prepared Detection Reagent A immediately.
Shake and mix. Incubate 1 hour at 37°C;
3. Aspirate and wash 3 times;
4. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
5. Aspirate and wash 5 times;
6. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
7. Add 50µL Stop Solution. Read at 450 nm immediately.
| Magazine | Citations |
| Acta Neurologica Scandinavica | Effect of carotid endarterectomy on brain damage markers Pubmed:27126899 |
| Acta Neurologica Scandinavica | Effect of carotid endarterectomy on brain damage markers. pubmed:27126899 |
| journal of neuroimmunology | Cytokines and biological markers in autoimmune GFAP astrocytopathy: The potential role for pathogenesis and therapeutic implications Pubmed: 31254929 |
| Cerebellum | Neurofilament Light Chain Is a Biomarker of Neurodegeneration in Ataxia Telangiectasia 33893614 |
| Medicine (Baltimore) | Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis 34678870 |
| J Clin Med | Fatty Acid-Binding Protein 7 (FABP-7), Glutamic Acid and Neurofilament Light Chain (NFL) as Potential Markers of Neurodegenerative Disorders in Psoriatic Patients … Pubmed:35566558 |
Share
